Related Experiment Video
Updated: Sep 27, 2026

Direct Mouse Trauma/Burn Model of Heterotopic Ossification
Published on: August 6, 2015
[Effects of selective and non-selective cyclooxygenase 2 inhibitors on heterotopic ossification in rat model with
Objective:
To compare the efficacy of selective cyclooxygenase 2 (COX2) inhibitor and non-selective COX2 inhibitor drugs in prevention of heterotopic ossification in rats model so as to provide reference for clinical drugs selection of heterotopic ossification prevention.
Methods:
Fifty male Sprague Dawley rats, 6 to 8 weeks old, weight (190.0 +/- 8.5) g, were selected; the right Achilles tendon was cut off to induce ectopic bone formation. The rats were randomly divided into 5 groups (n = 10): on the 1st day after modeling, celecoxib was given in groups A [2 mg/(kg x d)] and B [10 mg/(kg x d)], indomethacin in groups C [(2 mg/(kg x d) and D [10 mg/(kg x d)], and 2 mL of saline in group E for 10 weeks. The general condition of rats was observed after operation. At 5 and 10 weeks after operation, X-ray films of the right lower limb were taken to observe new bone formation. At 10 weeks after operation, the right Achilles tendon tissue was harvested for histological observation. Based on X-ray and histological results, heterotopic ossification was assessed. Immunohistochemical staining was used to evaluate COX2 and bone morphogenetic protein 2 (BMP-2) expression levels in local Achilles tendon.
Results:
During the experiment, 5 rats died (2 in group B, 1 in group C, and 2 in group D), the other rats survived to the end of the experiment. General observation of Achilles tendon tissue showed that the tendon tissue volume of group B was the smallest, with soft texture and no cartilage-like tissue; the tendon tissue volume of group E was the biggest, with hard texture and cartilage-like tissue. The incidence of heterotopic ossification was 80.0% (8/10), 25.0% (2/8), 88.9% (8/9), 50.0% (4/8), and 100% (10/10) in groups A-E respectively at 10 weeks after operation; significant differences were found between groups B, D and group E (P = 0.002, P = 0.023) and between groups B and C (P = 0.015), but no significant difference was found among the other groups (P > 0.05). COX2 expression level in groups B and D was significantly lower than that in group E (P < 0.05 ), but no significant difference was found among the other groups (P > 0.05); BMP-2 expression level in group B was significantly lower than that in groups A, C, and E (P < 0.05), but no significant difference was found among the other groups (P > 0.05).
Conclusion:
Celecoxib at a dose of 10 mg/(kg x d) can effectively reduce the incidence of heterotopic ossification in rats.
Insights
The selective cyclooxygenase 2 (COX2) inhibitor, celecoxib, at 10 mg/(kg x d) effectively reduced heterotopic ossification in a rat model. This finding provides valuable insights for selecting clinical treatments for heterotopic ossification.
Area of Science:
- Pharmacology
- Orthopedics
- Biomedical Research
Context:
- Heterotopic ossification (HO) is a debilitating condition characterized by abnormal bone formation.
- Current prevention strategies for HO lack definitive efficacy.
- Understanding the role of cyclooxygenase 2 (COX2) in HO pathogenesis is crucial.
Purpose:
- To evaluate and compare the efficacy of selective COX2 inhibitors versus non-selective COX2 inhibitors in preventing HO.
- To establish a reliable rat model for studying HO prevention.
- To provide a scientific basis for clinical drug selection in HO management.
Summary:
- A rat model of Achilles tendon injury was used to induce HO.
- Rats were treated with varying doses of celecoxib (selective COX2 inhibitor) or indomethacin (non-selective COX2 inhibitor), or saline.
- HO incidence, new bone formation, and expression of COX2 and BMP-2 were assessed via X-ray, histology, and immunohistochemistry.
Impact:
- The study demonstrates that celecoxib at 10 mg/(kg x d) significantly reduces HO incidence in rats.
- This research offers critical preclinical data supporting the use of selective COX2 inhibitors for HO prevention.
- Findings guide future clinical trials and therapeutic strategies for managing heterotopic ossification.

